Exercise interventions for people undergoing multimodal cancer treatment that includes surgery by Loughney, LA et al.
Cochrane Database of Systematic Reviews
Exercise interventions for people undergoingmultimodal
cancer treatment that includes surgery (Protocol)
Loughney LA, West MA, Kemp GJ, Grocott MPW, Jack S
Loughney LA, West MA, Kemp GJ, Grocott MPW, Jack S.
Exercise interventions for people undergoing multimodal cancer treatment that includes surgery.
Cochrane Database of Systematic Reviews 2016, Issue 7. Art. No.: CD012280.
DOI: 10.1002/14651858.CD012280.
www.cochranelibrary.com
Exercise interventions for people undergoing multimodal cancer treatment that includes surgery (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iExercise interventions for people undergoing multimodal cancer treatment that includes surgery (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Exercise interventions for people undergoing multimodal
cancer treatment that includes surgery
Lisa A Loughney1 ,2, Malcolm A West1,2,3, Graham J Kemp2,4, Michael PW Grocott1,2, Sandy Jack1,2
1Anaesthesia and Critical Care Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
2Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences, University of Southampton, Southampton,
UK. 3Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. 4Department of Mus-
culoskeletal Biology and MRC - Arthritis Research UK Centre for Integrated research into Musculoskeletal Ageing (CIMA), Faculty
of Health and Life Sciences, University of Liverpool, Liverpool, UK
Contact address: Lisa A Loughney, Anaesthesia and Critical Care Research Unit, University Hospital Southampton NHS Foundation
Trust, Southampton, UK. ll2y12@soton.ac.uk. Lisa.Loughney@uhs.nhs.uk.
Editorial group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group.
Publication status and date: Edited (no change to conclusions), published in Issue 9, 2016.
Citation: Loughney LA, West MA, Kemp GJ, Grocott MPW, Jack S. Exercise interventions for people undergoing multi-
modal cancer treatment that includes surgery. Cochrane Database of Systematic Reviews 2016, Issue 7. Art. No.: CD012280. DOI:
10.1002/14651858.CD012280.
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the effect of exercise interventions for people undergoing multimodal treatment including surgery on physical fitness,
safety and feasibility, health-related quality of life and other important health outcomes.
B A C K G R O U N D
Description of the condition
People with cancer are often faced with multimodality treatment
that includes surgery in combination with other treatments, such
as chemotherapy, radiotherapy and immunotherapy. These treat-
ments are of two kinds: adjuvant treatment is given after surgery
to treat residual disease, in order to minimise the likelihood of
tumour recurrence or spread (Papadimitriou 2015), whereas the
aim of neoadjuvant treatment is to reduce tumour bulk prior to
surgery, in order to improve the likelihood of a complete surgical
resection of the cancer (Chau 2006). Major surgery is associated
with significant morbidity and mortality, as recently highlighted
in the European Surgical Outcome Study (Pearse 2012), and mor-
bidity has amajor impact on postoperative recovery, quality of life,
and survival (Khuri 2005; Moonesinghe 2014).
Cancer is frequently associated with cachexia (body weakness
and wasting), which can worsen perioperative outcomes (Brown
1991). This condition can be exacerbated by chemotherapy, which
is associated with muscle wasting and dysfunction. Furthermore,
cancer treatment has been linked to decreased physical fitness, ap-
parently related to the type of treatment, being worse in those re-
ceiving surgery and radiotherapy in combination with chemother-
apy than in those receiving radiotherapy or surgery alone (Moros
2010). Moreover, this decrease in physical fitness may persist. In a
series of studies, cardiorespiratory fitness was around 30% below
that of age-matched sedentary healthywomenup to three years fol-
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lowing completion of adjuvant treatment for breast cancer (Jones
2007). A significant decrease in physical activity has been associ-
ated with a higher level of fatigue during breast cancer treatment
(Mock 2005). Poor physical fitness reflects reduced physiological
reserve, which predisposes people undergoing surgery to postop-
erative complications (West 2011; Hennis 2012; Moran 2016).
Description of the intervention
For the purposes of this review, we define an exercise intervention
as a prescribed period of aerobic physical activity, involving large
muscle groups, with aminimumof three planned exercise sessions,
each session lasting at least 10 minutes (O’Doherty 2013). The
intervention may take place in any setting and be delivered to a
group or to an individual participant; however, it must be super-
vised or delivered by a trainer or healthcare professional.
How the intervention might work
Higher physical fitness has been associated with improved progno-
sis in solid tumours (Jones 2013), longer cancer-specific survival,
and lower cancer-related mortality (Brunelli 2014). Remaining
physically active during and after cancer treatment could there-
fore be an important way of reducing associated adverse effects,
improving overall survival, and reducing the rate of tumour recur-
rence (Thomas 2014). It has been shown that women with non-
metastatic colorectal cancer who were physically active following
diagnosis had a significantly lower risk of death than those who
were not physically active (Meyerhardt 2006). Similarly, women
with breast cancer who exercised at moderate intensity (i.e. at least
30 minutes per day on at least five days per week) were shown
to have a reduced risk of death (Holmes 2005). Exercise train-
ing stimulates skeletal muscle adaptations such as increased mito-
chondrial content and improved oxygen uptake capacity (Holloszy
1984), both contributors to physical fitness. In combination with
chemotherapy, exercise training has been shown to slow tumour
progression in solid tumours compared with chemotherapy alone
(Betof 2015). Exercise training may also reduce chronic inflam-
mation, which has been associated with worse outcomes in people
living with cancer (Proctor 2011).
Why it is important to do this review
Studies in people undergoing multimodal cancer treatment, in the
form of neoadjuvant chemotherapy and chemoradiotherapy and
surgery, for upper and lower gastrointestinal cancer, suggest that
the reduced physical fitness associatedwith these treatmentmodal-
ities may be linked to higher in-hospital morbidity and mortality
at one year post-treatment (Jack 2014; West 2014). The litera-
ture covering the effects of an exercise intervention to improve
physical fitness in people with cancer undergoing single modality
treatment has been synthesised in a number of systematic reviews.
Two systematic reviews in people with non-small cell lung cancer
(NSCLC) reported beneficial effects on physical fitness and other
important clinical measures following participation in an exer-
cise intervention in people who were treated surgically (Crandall
2014), and beneficial effects on physical fitness, symptoms and
health-related quality of life (HRQoL) in people who were treated
by surgery or a form of cancer treatment (Granger 2011). Two
other systematic reviews in people with cancer (different cancer
types) found evidence that exercise training in people who were
surgically treated improved urinary continence (prostate cancer),
cardiorespiratory fitness, and length of stay (Singh 2013) and im-
proved HRQoL in people who received cancer treatment (Mishra
2012). However, to the best of our knowledge, there are no sys-
tematic reviews specifically addressing the effects of an exercise
intervention on physical fitness and other important clinical out-
comes in people with cancer undergoing multimodality treatment
that includes surgery.
O B J E C T I V E S
To determine the effect of exercise interventions for people un-
dergoing multimodal treatment including surgery on physical fit-
ness, safety and feasibility, health-related quality of life and other
important health outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider only randomised controlled trials (RCTs) for
inclusion.
Types of participants
We will include studies that evaluate the effect of an exercise inter-
vention in adults (18 years and over) with a confirmed cancer diag-
nosis requiringmultimodal cancer treatment that includes surgery,
of any age, regardless of gender, tumour type, tumour stage and
type of cancer treatment, and of any exercise/activity level.
Types of interventions
Any exercise intervention that involves a prescribed period of aer-
obic physical activity, involving large muscle groups, with a min-
imum of three planned exercise sessions, each session lasting at
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least 10 minutes, delivered by trained personnel or a healthcare
professional. The intervention may take place in any setting and
be delivered to a group or to an individual participant. We will
include studies of exercise counselling interventions or prescribed
exercise only, such as prescribed daily walking. We expect that in-
terventions will vary to some extent with regard to the timing of
initiation, duration and content.
Types of outcome measures
Primary outcomes
• Physical fitness (a measure of physical fitness and physical
activity)
• Safety and feasibility ((number of adverse events and
adherence to the intervention (attrition rate and reasons for
withdrawal))
Secondary outcomes
• Health-related quality of life (HRQoL)
• Fatigue
• Postoperative outcome (morbidity, disease-free survival at
12 months, overall survival at five years)
Search methods for identification of studies
Electronic searches
We will search the following electronic databases up to the latest
issue to obtain relevant studies for this review: Cochrane Central
Register of Controlled Trials (CENTRAL, latest issue); MED-
LINE; EMBASE: SPORTDiscus. We present theMEDLINE (via
Ovid) search strategy in Appendix 1. For databases other than
MEDLINE, we will adapt the search strategy accordingly. We will
apply no language or date restrictions in the searches.
Searching other resources
We will also perform an expanded search for articles to identify
’grey literature’. This will include:
• Handsearching of reference lists of all articles, texts and
other review articles on exercise and cancer;
• PubMed: ’Related articles’ feature;
• Web of Science: citation search of key authors;
• Clinical trials registers search: Clincaltrials.gov and the
WHO International Clinical Trials Registry Platform (
apps.who.int/trialsearch/) for ongoing trials and trial protocols;
• Unpublished literature through searches of conference
proceedings;
• Attempts to contact study authors for missing data and
information related to study methods.
Data collection and analysis
Selection of studies
We will import all records retrieved from the searches into the
reference management software package EndNote. We will then
remove duplicates and select relevant articles for screening. Two
review authors (LL and MAW) will examine the remaining refer-
ences independently. We will exclude those studies which clearly
do not meet the inclusion criteria. We will obtain full-text copies
of potentially relevant references.Wewill resolve any disagreement
between the two review authors (LL and MAW) through discus-
sion or, if required, we will resolve disagreements by recourse to
a third review author (SJ). We will link together multiple records
on the same study and document the selection process in the Cov-
idence web-based software platform. We will exclude case reports
and theses.
Data extraction and management
Two review authors (LL and MAW) will independently extract
study characteristics and outcome data, in accordance with pre-
defined criteria, to a data collection form (Excel). We will retrieve
full texts of all studies in which the abstract refers to an exercise
intervention in people with cancer, and studies for which there is
no abstract but the title suggests relevance. We will note in the
’Characteristics of included studies’ table if outcome data were not
reported in a usable way. One review author (LL) will transfer data
into the Review Manager 2014 (RevMan) file and will double-
check that the data are entered correctly by comparing the data en-
tered into RevMan with the study reports. A second review author
(MAW) will spot-check study characteristics for accuracy against
the trial report. For included studies, we will extract the following
data:
1. Study details
• Author, country and year of publication
• Study aim
• Sample size
• Study design, methodology
• Duration of follow-up
• Study funding source
• Declarations of conflict of interest
2. Participant characteristics
• Cancer type
• Cancer treatment
• Age
• Gender
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• Ethnicity
3. Intervention details
• Exercise prescription components (frequency, intensity,
time, type)
• Setting (in-hospital, community-based, home-based)
• Randomisation details
• Specified follow-up time points
• Safety and feasibility (number of adverse events and
adherence to the intervention (attrition rate and reasons for
withdrawal)
• Categorisation of the intervention (e.g. supervised,
independent, educational)
4. Comparison details
• Description of usual-care control groups
• Additional information if appropriate
5. Outcomes: Primary and secondary outcomes; method of out-
come measurement and time point of outcome measurement.
Assessment of risk of bias in included studies
Two review authors (LL and MAW) will independently assess and
score the methodological quality of each study in accordance with
the Cochrane tool for assessing risk of bias (Higgins 2011). This
tool has the following seven domains:
• Random sequence generation
• Allocation concealment
• Blinding of participants and personnel
• Blinding of outcome assessment
• Incomplete outcome data
• Selective reporting
• Other potential sources of bias
Two review authors (LL and MAW) will apply the ’Risk of bias’
tool independently, and will resolve differences by discussion with
a third review author (SJ). We will summarise results in both a
’Risk of bias’ graph and a ’Risk of bias’ summary figure. We will
score each item according to the criteria set out by Higgins 2011,
and will provide a quote from the study report and/or a statement
of justification for the judgement for each item in the ’Risk of bias’
table. When interpreting treatment effects and meta-analyses, we
will take into account the risk of bias for the studies that contribute
to that outcome.
Measures of treatment effect
For continuous outcomes (e.g. physical fitness/activity and
HRQoL), wewill extract the point estimate for themeasure of cen-
tral tendency for the final value of the outcome of interest and the
number of participants assessed at stated follow-up in each treat-
ment arm, to estimate the standardised mean difference (SMD)
between treatment arms and its 95% confidence interval (CI). For
dichotomous outcomes, wewill extract the number of participants
in each treatment arm who experienced the outcome of interest
and the number of participants assessed at follow-up, to estimate a
risk ratio (RR) with 95% CI. For time-to-event outcomes, we will
extract the log hazard ratio (HR) and its standard error, assuming
that the hazard ratio is constant over time. If we are unable to
obtain the standard error, we will attempt to obtain the CI or P
value to calculate it. In cases where we cannot obtain sufficient
data for hazard radios, we will dichotomise the data.
Dealing with missing data
We will attempt to contact study authors to obtain missing data
(participant, outcome, or summary data). We will report the level
of loss to follow-up and assess this as a source of potential bias.
We will document reasons for missing data. We will analyse par-
ticipants in their assigned groups using intention-to-treat analysis
where appropriate.When intention-to-treat has not been used, we
will note this in the ’Risk of bias’ assessment under ’Incomplete
outcome data’, and will use available-case analysis if feasible and
appropriate.
Assessment of heterogeneity
Where we consider studies to be similar enough (based on consid-
eration of participants, cancer treatment, exercise training char-
acteristics or outcome measures), we will use clinical expertise to
decide whether it is appropriate to combine trials in a meta-anal-
ysis. We will assess the degree of heterogeneity by visual inspec-
tion of forest plots, by estimation of the percentage of heterogene-
ity (I² measurement) between trials which cannot be ascribed to
sampling variation (Higgins 2003), by a formal statistical test of
the significance of the heterogeneity (Chi²) (Deeks 2001) and, if
possible, by subgroup analyses. We will regard heterogeneity as
substantial if I² is greater than 30% and either Tau² is greater than
zero, or there is a low P value (< 0.10) in the Chi² test for hetero-
geneity.
Where we have concerns regarding clinical, methodological or
statistical heterogeneity across included studies, we will not report
pooled results frommeta-analysis.Wewill use a narrative approach
to data synthesis and report possible clinical or methodological
reasons for this.
Assessment of reporting biases
We will examine funnel plots corresponding to meta-analysis of
the primary outcome to assess the potential for small-study effects
such as publication bias if we include more than 10 studies in an
analysis.
Data synthesis
We will carry out statistical analysis using a random-effects
model with inverse variance weighting for all meta-analyses
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(DerSimonian 1986). We will consider the random-effects sum-
mary as the average range of possible treatment effects and will
discuss the clinical implications of treatment effects differing be-
tween studies. We will present results as the average treatment ef-
fect with its 95% CI, and the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analyses where there are sufficient data
according to:
• Cancer type (solid and haematological tumours);
• Cancer treatment (neoadjuvant, adjuvant chemotherapy,
adjuvant radiotherapy, immunotherapy);
• Exercise intervention characteristics (frequency, intensity,
timing, type);
• Participant characteristics (gender and age).
Sensitivity analysis
We will conduct a sensitivity analysis to assess the effects of in-
cluding trials with a high risk of bias.
Summary of findings table
Two review authors (LL and MAW) will independently rate the
certainty of the evidence for each outcome. (GRADE Working
Group 2004).
We will create a Summary of findings table in GRADEpro GDT
using theGRADE approach (GRADEWorkingGroup 2004). For
assessments of the overall certainty of evidence for each outcome
that includes pooled data from RCTs only, we will downgrade the
evidence from ’high certainty’ by one level for serious (or by two
for very serious) study limitations (risk of bias), indirectness of
evidence, serious inconsistency, imprecision of effect estimates or
potential publication bias. Wewill include the following outcomes
in the Summary of findings table:
• Physical fitness (including physical capacity and physical
activity)
• Safety and feasibility
• HRQoL
• Fatigue
• Post-operative outcome (morbidity, overall survival at 5
years, disease free survival at 12 months)
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A P P E N D I C E S
Appendix 1. MEDLINE Ovid search strategy
1. exp Neoplasms/
2. (neoplas* or carcinoma* or adenocarcinoma* or malignan* or cancer* or tumor* or tumour*).ti.
3. 1 or 2
4. exp Surgical Procedures, Operative/
5. surgery.fs.
6. (surgery or surgical).ti.
7. 4 or 5 or 6
8. exp Combined Modality Therapy/
9. (combined modality or multimodal* or multi modal*).ti.
10. drug therapy.fs.
11. exp Antineoplastic Agents/
12. Antineoplastic Combined Chemotherapy Protocols/
13. chemotherap*.ti.
14. exp RAdiotherapy/
15. radiotherapy.fs.
16. (radiotherap* or irradiat* or radiat*).ti.
17. exp Immunotherapy/
18. immunotherap*.ti.
19. ((adjuvant or neoadjuvant or neo-adjuvant) adj3 therap*).ti.
20. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
21. exp Exercise/
22. exp Exercise Therapy/
23. exp Exercise Movement Techniques/
24. Physical Fitness/
25. exp Physical Endurance/
26. exp Muscle Strength/
27. Muscle Fatigue/
28. (exercis* or movement* or stretch* or aerobic* or anaerobic*).ti.
29. ((resistance adj3 train*) or stamina or (physical adj3 fit*) or ((musc* or neuromisc*) adj3 fatigue)).ti.
30. (walk* or swim* or cycl* or run* or yoga or tai chi or pilates).ti.
31. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
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32. 3 and 7 and 20 and 31
33. randomized controlled trial.pt.
34. controlled clinical trial.pt.
35. randomized.ab.
36. placebo.ab.
37. clinical trials as topic.sh.
38. randomly.ab.
39. trial.ti.
40. 33 or 34 or 35 or 36 or 37 or 38 or 39
41. 32 and 40
Key:
mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
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